Process for producing poxviruses and poxvirus compositions
Inventors
Malarme, Daniel • Cordier, Yves • Sene, Claude
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8415134-B1
Publication Date
2013-04-09
Expiration Date
Abstract
The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.
Core Innovation
The invention relates to a process for purifying a poxvirus composition from cell culture supernatant and cultured packaging cells infected with a wild type, an attenuated, and/or a recombinant poxvirus with no targeted infection specificity. The process recovers poxvirus particles from the cell culture supernatant and from cultured packaging cells disrupted by a high speed homogenizer to obtain a poxvirus particle mixture, which is clarified by depth filtration to remove cellular debris.
The clarified poxvirus particle mixture is concentrated by microfiltration and diafiltered to obtain a composition of a wild type, an attenuated, and/or a recombinant poxvirus with no targeted infection specificity. The resulting poxvirus composition comprises intracellular mature virus (IMV) and extracellular enveloped virus (EEV) with more than 1% EEV.
The process is free from animal products and does not use nuclease. The invention thereby provides a purified poxvirus composition containing an enriched EEV fraction while maintaining the poxvirus as having no targeted infection specificity.
Claims Coverage
The partial content provides one independent claim, which defines a purification process yielding a poxvirus composition with IMV and EEV and more than 1% EEV, under conditions that are free from animal products and do not use nuclease.
Purifying a poxvirus composition without targeted infection specificity and with nuclease-free, animal-product-free workflow
A process for purifying a poxvirus composition from cell culture supernatant and cultured packaging cells infected with a wild type, an attenuated, and/or a recombinant poxvirus with no targeted infection specificity, by recovering poxvirus particles after disruption by high speed homogenizer, clarifying by depth filtration, concentrating by microfiltration, and diafiltering, wherein the process is free from animal products and does not use nuclease, and wherein the poxvirus composition comprises IMV and EEV with more than 1% EEV.
The claim coverage centers on a purification process that produces a poxvirus composition enriched in EEV (>1%) and is defined as free from animal products and without nuclease, while maintaining poxvirus with no targeted infection specificity.
Stated Advantages
Produces a poxvirus composition comprising IMV and EEV with more than 1% EEV.
The process is free from animal products.
The process does not use nuclease.
Documented Applications
No documented applications found
Interested in licensing this patent?